Loading...
•
Dec 31, 2023
TELA Bio Q4 2023 Earnings Report
Achieved record fourth quarter and full year revenues and reported complete financial results.
Key Takeaways
TELA Bio reported a 46% increase in revenue for Q4 2023, reaching $17.0 million. The company's gross profit was $11.6 million, representing 68% of revenue. Net loss for the quarter was $12.9 million. The company launched LIQUIFIX devices and the upcoming launch of OviTex IHR suite of products.
Revenue increased by 46% compared to the same period in 2022, reaching $17.0 million.
Gross profit was $11.6 million, or 68% of revenue.
Operating expenses increased to $23.9 million due to higher compensation costs and employee-related expenses.
Net loss was $12.9 million, compared to a net loss of $10.0 million in the same period in 2022.
Forward Guidance
Full year 2024 revenue is projected to range from $74.0 million to $76.0 million, representing growth of 27% to 30% over full year 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...